Dongfeng Long and Singleron Biotechnologies Announce Strategic Collaboration to Advance Cell Therapy Manufacturing

Tofflon Official WeChat, March 23: On March 21, Xingyiang (Shanghai) Biotechnology Co., Ltd. ("Xingyiang") officially signed a strategic cooperation agreement with Tofflon. In the future, the two parties will engage in in-depth and comprehensive cooperation in the field of cell therapy production processes. Xingyiang will provide process technology and testing, while Tofflon will supply domestically customized equipment and consumables. Together, they will promote more effective cost reduction and efficiency improvement for cell therapy drugs, achieve the strategic goal of domestic substitution more quickly, and further advance the industry.